Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug

Summary: The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible. Here, we identify sphingomyelin phosphodiesterase 1 (SMPD1), an enzyme that regulates the con...

Full description

Bibliographic Details
Main Authors: Junfeng Bi, Atif Khan, Jun Tang, Aaron M. Armando, Sihan Wu, Wei Zhang, Ryan C. Gimple, Alex Reed, Hui Jing, Tomoyuki Koga, Ivy Tsz-Lo Wong, Yuchao Gu, Shunichiro Miki, Huijun Yang, Briana Prager, Ellis J. Curtis, Derek A. Wainwright, Frank B. Furnari, Jeremy N. Rich, Timothy F. Cloughesy, Harley I. Kornblum, Oswald Quehenberger, Andrey Rzhetsky, Benjamin F. Cravatt, Paul S. Mischel
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Cell Reports
Subjects:
glioblastoma
sphingolipid metabolism
SMPD1
fluoxetine
Membrane lipids
EGFR signaling
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124721014340

Similar Items

Similar Items